Positive news for patients of any HCV genotypes! After treatment with AbbVie’s new pangenotypic regimen of glecaprevir/pibrentasvir, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy.
VIDEO: Pangenotypic regimen leads to ... - HFI Connect - Hep...
VIDEO: Pangenotypic regimen leads to high SVR in all HCV genotypes
Written by
HFIAdmin
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Hepatitis E
I got infected by Hepatitis E two months ago and i am still suffering from this. My highest...
Overwhelmed
Hi everyone, I'm new to this site and really just looking for somewhere I can talk to people that...
